Cyclerion Therapeutics, Inc.
CYCN
$3.79
-$0.12-3.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -43.24% | 351.03% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -43.24% | 351.03% | -- |
| Cost of Revenue | -- | 1,927.78% | 826.79% | 329.63% | -46.67% |
| Gross Profit | -- | -1,722.22% | -71.09% | 366.37% | 135.24% |
| SG&A Expenses | 3.63% | 65.05% | 7.69% | 23.53% | 33.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.34% | 108.65% | 42.87% | 42.28% | 27.53% |
| Operating Income | -5.92% | -120.25% | -266.93% | 10.82% | -20.81% |
| Income Before Tax | -441.67% | -122.32% | -250.75% | -34.99% | 75.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -441.67% | -122.32% | -250.75% | -34.99% | 75.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -441.67% | -122.32% | -250.75% | -34.99% | 75.49% |
| EBIT | -5.92% | -120.25% | -266.93% | 10.82% | -20.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -291.28% | -35.13% | -200.58% | -5.73% | 79.97% |
| Normalized Basic EPS | 22.75% | -35.15% | -200.54% | -5.70% | -1.46% |
| EPS Diluted | -291.28% | -171.06% | -200.58% | -5.73% | 79.97% |
| Normalized Diluted EPS | 22.75% | -35.15% | -200.54% | -5.70% | -1.46% |
| Average Basic Shares Outstanding | 38.42% | 64.51% | 49.92% | 27.67% | 22.35% |
| Average Diluted Shares Outstanding | 38.42% | 64.51% | 49.92% | 27.67% | 22.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |